Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Autolus Therapeutics (AUTL) Non Operating Income (2017 - 2025)

Autolus Therapeutics' Non Operating Income history spans 6 years, with the latest figure at -$3.5 million for Q4 2025.

  • For Q4 2025, Non Operating Income fell 115.91% year-over-year to -$3.5 million; the TTM value through Dec 2025 reached -$6.0 million, down 171.9%, while the annual FY2025 figure was $515000.0, 97.69% down from the prior year.
  • Non Operating Income reached -$3.5 million in Q4 2025 per AUTL's latest filing, down from $84000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $22.1 million in Q4 2024 to a low of -$23.9 million in Q4 2023.
  • Average Non Operating Income over 4 years is -$1.9 million, with a median of -$811000.0 recorded in 2022.
  • The largest YoY upside for Non Operating Income was 192.51% in 2024 against a maximum downside of 10538.24% in 2024.
  • A 4-year view of Non Operating Income shows it stood at -$945000.0 in 2022, then plummeted by 2431.64% to -$23.9 million in 2023, then soared by 192.51% to $22.1 million in 2024, then crashed by 115.91% to -$3.5 million in 2025.
  • Per Business Quant, the three most recent readings for AUTL's Non Operating Income are -$3.5 million (Q4 2025), $84000.0 (Q3 2025), and $135000.0 (Q2 2025).